Conceptus, Inc. (Nasdaq:CPTS) announced that management is planning to present at the Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 10:30 a.m. Eastern time at the Grand Hyatt New York in New York City. A live webcast of the presentation will be available on the company’s website at www.conceptus.com. When accessing the webcast through the Conceptus site, select “Investors” then select “Events and Presentations.” The archived replay will be available for approximately 90 days following the live presentation.

Conceptus, Inc. designs, develops, and markets minimally invasive devices for reproductive medical applications.

*********************************************

Biomass use can be considered part of the terrestrial carbon cycle-the balanced cycling of carbon from the atmosphere into plants and then into soils and the atmosphere during plant decay. When biopower is developed properly, emissions of biomass carbon are taken up or recycled by subsequent plant growth within a relatively short time, resulting in low net carbon emissions.

Beneficial biomass sources generally maintain or even increase the stocks of carbon stored in soil or plants. Beneficial biomass also displaces carbon emissions from fossil fuels, such as coal, oil or natural gas, the burning of which adds new and additional carbon to the atmosphere and causes global warming.

Cleantech Transit Inc. (”Cleantech”) (OTC.BB:CLNO) was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. Cleantech Transit Inc has expanded its focus to invest directly in specific green projects that could maximize shareholder value. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech Transit Inc. has selected to invest in Phoenix Energy (www.phoenixenergy.net).

Cleantech Transit Inc. is pleased to provide additional details after achieving success on the 500 KW facility and successfully moving past the interconnection testing stage.

Coming on the recent success at the 500KW facility in Merced, California this poises Phoenix Energy to become a leading developer of renewable biomass distributed generation plants that utilize local resources for local energy.

Currently there are two additional projects being pre-certified by Phoenix Energy in California. The projects are each projected to be 1 MW biomass gasification facilities that will provide both electricity and process heat energy. Each facility will provide enough electricity to power approximately 800 homes as well as process heat to be used in drying agricultural products. The projects are expected to complete by the end of 2012.

Cleantech will be providing details on the expecting closing date of its initial investment into Phoenix Energy in the coming weeks.

To discover more about CLNO, Please visit: http://www.cleantechtransitinc.com/

*********************************************

All too frequently, people are discovering that a grandparent, parent, elderly relative, or friend can no longer remember names or faces, recognize common objects, or talk in coherent sentences. This person may be suffering from Alzheimer’s disease (AD). Alzheimer’s disease is a growing medical and social concern. In the last 30 years, AD has become a hot topic in both the medical and non-medical communities.

Power3 Medical Products, Inc. (OTC.BB:PWRM) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

The NuroPro Blood Test is Power3’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease . Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

The NuroPro Test is currently in the development stages. The company has completed proof-of-concept and clinical validation studies, with results exceeding expectations. Currently, Power3 has commenced a three hundred patient clinical validation study of its NuroPro diagnostic test for Alzheimer’s disease and Parkinson’s disease.

For more information about Power3 Medical Products, Inc. visit its website http://www.power3medical.com

*********************************************

All of EntreMed’s product candidates are orally-administered compounds that have demonstrated potential in oncology and inflammatory diseases. The Company will continue to target its resources for the clinical development of its priority program, ENMD-2076, which is currently in multiple Phase 1 oncology studies and a multi-center Phase 2 study in ovarian cancer. Our other clinical product candidates (MKC-1 and ENMD-1198) continue to be in various stages of Phase 1 and 2 oncology studies but would require additional significant funding to further clinical investigation. In addition to our oncology drug candidates, we have a Phase 1 candidate, Panzem®, for the treatment of rheumatoid arthritis.

EntreMed, Inc. (Nasdaq:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. The data were presented by the principal investigator for the study, Dr. Ursula A. Matulonis, medical director of gynecologic oncology at Dana-Farber Cancer Institute and associate professor of medicine, Harvard Medical School, during a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2011 in Chicago, Illinois.

The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer. The study was conducted at six sites in the United States and Canada and included Dana-Farber Cancer Institute, Indiana University Melvin & Bren Simon Cancer Center, University of Chicago Medical Center, Memorial Sloan-Kettering Cancer Center, University of Colorado Cancer Center, and Princess Margaret Hospital. Sixty-four patients were enrolled of which 57 were evaluable at the time of the presentation. The primary endpoint for the study was progression-free survival rate at six months. Secondary end-points include response rate, duration of response, and overall survival.

ENMD-2076 demonstrated clinical activity when administered daily orally as a single agent. Interim data from 57 evaluable patients showed a six-month progression free survival rate of 19%. Of the evaluable patients, four patients achieved a partial response and 30 patients achieved stable disease as measured by RECIST v1.1. Median overall survival has not yet been reached. The side effect profile was consistent with activity against ENMD-2076’s targets, in particular, VEGFR2 and Aurora A. Studies to evaluate potential markers of ENMD-2076 in this patient group are ongoing.

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

*********************************************

The Board of Directors of Fauquier Bankshares, Inc. (Nasdaq:FBSS) recently announced a quarterly dividend of $0.12 per share. This dividend was declared for shareholders of record as of the close of business on June 17, 2011 and will be payable on July 1, 2011. The $0.12 per share dividend represents a $0.48 dividend on an annualized basis.

Fauquier Bankshares, Inc. operates as a holding company for The Fauquier Bank that provides consumer and commercial banking services to individuals, businesses, and industries in Virginia.

*********************************************

Logitech International SA (Nasdaq:LOGI) unveiled its latest selection of coordinated, must-have computer accessories, the Logitech Color Collection. A fresh update to one of the company’s most popular lines, this new collection features bright, juicy colors and layered designs that make it easy for you to infuse your digital life with a touch of personality. “We’re adding a creative twist to our most popular products,” said Rory Dooley, Logitech’s senior vice president and general manager of the Control Devices business unit. “With designs ranging from craft punk to cyber chic, and from homespun to high-def, the Logitech Color Collection lets consumers see how technology can help power human expression without compromising on quality or substance.”

Logitech International S.A. engages in the development and marketing of products in PC navigation, Internet communications, digital music, home-entertainment control, gaming, and wireless devices.

*************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (CLNO.OB).

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

The H.J. Heinz Company (NYSE:HNZ) announced that its Board of Directors declared quarterly dividends on both common and preferred stock.

The Heinz common stock dividend will be increased from 45.0 cents to 48.0 cents quarterly for all shareholders of record as of June 24, 2011, payable July 10, 2011. The new annualized dividend is $1.92, which represents an increase of $0.12, or 6.7%, versus last year’s dividend. Including this announcement, Heinz has increased the dividend almost 80% since Fiscal 2004, a compound annual growth rate of 7.5%.

H. J. Heinz Company manufactures and markets food products for consumers, foodservice, and institutional customers. It offers ketchup, condiments and sauces, frozen food, soups, desserts, entrees, snacks, frozen potatoes, appetizers, beans and pasta meals, infant nutrition, and other processed food products.

************************************************

The symptoms of Parkinson’s disease include tremors or trembling (shaking hands are often the most telltale signs of it); difficulty maintaining balance and coordination; trouble standing or walking; stiffness; and general slowness. A person with Parkinson’s may have trouble smiling, talking, or swallowing. Their faces may appear flat and without expression, but people with Parkinson’s continue to have feelings - even though their faces don’t always show it. Sometimes people with the disease can have trouble with thinking and remembering, too.

Power3 Medical Products, Inc. (OTC.BB:PWRM) applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

The NuroPro Blood Test is Power3’s medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

Please visit Power3 Medical Products, Inc website http://www.power3medical.com.

************************************************

Gold is a yellow soft malleable metal considered valuable, both as an investment and as an adornment. Chemically, gold does not react with most chemicals, but is affected by chlorine, fluorine, aqua regia and cyanide. Gold dissolves in mercury, forming amalgam alloys, but does not react with it. Gold is insoluble in nitric acid, which will dissolve silver and base metals, and this is the basis of the gold refining technique known as “inquartation and parting”. Nitric acid has long been used to confirm the presence of gold in items, and is the origin of the colloquial term “acid test,” referring to a gold standard test for genuine value.

Hondo Minerals Corporation (HMNC.OB) is engaged in the acquisition of mines, mining claims and mining real estate in the United States, Canada and Mexico with mineral reserves of precious metals or non-ferrous metals.

Hondo owns the Tennessee and Schuylkill Mines in Chloride, Arizona. The Tennessee Mine was the largest producing silver mine in Arizona history. The Tennessee Mine operated from the late 1800’s until 1947 producing lead, zinc, gold and silver. The Company also owns numerous other mining claims in the US Southwest, which are being evaluated for additional reserves.

Hondo Minerals Corporation is pleased to announce that it has just acquired over $500,000 dollars of additional E-Leech equipment for its Tennessee Mine production facility.

E-Leech technology is a patent pending process that creates a leaching process without the use of hazardous chemicals such as cyanide at its Tennessee Mine processing plant.

Toxic chemicals previously used such as Hydrochloric and Nitric Acid are replaced with a water-based and pH adjusted medium to leach precious and base metals from mine tailings that is safe to humans and the environment.

Electrochemical processes are used to generate pH levels low enough to leach metals such as Gold, Silver, Zinc and Rare Earths into a solution for recovery at an extremely low cost per ton.

For more information please visit: http://www.hondominerals.com

************************************************

Emerson (NYSE:EMR) announced that, effective June 1, 2011, D. Scott Barbour will be named executive vice president of Emerson and business leader of Emerson Network Power Systems, headquartered in Columbus, Ohio. Edward K. Feeney, who has been business leader since 2007, will become chairman of Emerson Network Power Systems.

Emerson Electric Co., a diversified global technology company, engages in designing and supplying product technology, as well as delivering engineering services and solutions to various industrial, commercial, and consumer markets worldwide.

************************************************

Hospira, Inc. (NYSE:HSP) announced that the company will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011. The presentation is scheduled to begin at 8:40 a.m. Pacific time on Wednesday, June 8, 2011. It will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira’s website at www.hospirainvestor.com.

Hospira, Inc., a specialty pharmaceutical and medication delivery company, develops, manufactures, and markets pharmaceuticals and medication delivery systems in the United States and internationally.

*************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars ($25,000) in cash from a third party (Friona Gold, LLC) for 1 week of media advertisement services for Hondo Minerals Corporation (HMNC.OB)

Immersion Corporation (Nasdaq:IMMR) announced the addition of new licensees of its technology for implementation into a wide variety of markets and applications. New licensees include: GoodBetterBest Ltd.: The manufacturer of the industry-leading Giotek brand in Europe, GoodBetterBest has recently licensed Immersion’s haptic technology for use in console gaming peripherals. Giotek was recently named the UK’s top Peripheral & Accessories brand at the MCV Industry Excellence Awards. National Research Council of Canada (NRC): NRC develops and distributes medical simulators; its NeuroTouch system is a virtual reality surgical simulator which uses MRI imaging, advanced soft-tissue modeling, and Immersion’s haptic technology to provide an advanced interface allowing surgeons to train and rehearse procedures and “feel” the texture of the virtual brain.

Immersion Corporation develops, manufactures, licenses, and supports a range of hardware and software technologies and products that enhance digital devices with touch interaction.

************************************************

Cleantech Transit Inc. (”Cleantech”) (OTC.BB:CLNO) is pleased to announce that the previously announced 500 KW biomass gasification facility located in Merced, California has successfully passed its interconnection tests and is now connected to the utility distribution grid.

The gasification technology uses a non-combustion process to convert Ag and other woody residues into a hydrogen rich gas (”syngas”), which is then converted into electricity, along with heat and biochar (a useful byproduct that captures carbon in solid form and can be used as a soil amendment).

The Phoenix Energy technology used in Merced essentially cooks the biomass in an oxygen-deprived environment to release the elemental gasses from the wood. In the process biomass is converted into a carbon rich biochar. With the carbon fixed in solid form this process not only provides a valuable soil amendment but also serves as a source of carbon sequestration.

The Merced plant is expected to produce enough electricity to power about 400 homes. The plant connected to the electricity grid under California’s feed-in-tariff with a 15-year power purchase agreement.

Gasification is the process in which a carbon-based, high-caloric material also known as municipal solid waste (MSW) (i.e. anything other than glass, masonry, metals and nuclear waste) goes through a thermal transformation process in an oxygen-deprived environment in which it is converted into a variety of products: an inert ash, various chemicals, synthesis gas (syngas) and is a proven technology currently deployed internationally.

Features and Benefits Include the Following:

Depending on operating hours, change filters roughly once a week (15 min), change biochar separation grate once a month (30 min), top end rebuild once per year (8 hours).

Small physical dimensions:

While individual setups may vary, the complete installation of a PHX-1000 requires approximately 3/4 - 1 acre.

Keeps you always up and running:

Grid parallel operation - pull power from either source seamlessly. The hurricane is over in two days but the power is out for two weeks? Not with a PHX-1000! If you have biomass waste, you have power.

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects that can maximize shareholder value. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project can generate shareholder returns as well benefit the Company’s manufacturing clients worldwide.

To discover more about CLNO, Please visit: http://www.cleantechtransitinc.com/

************************************************

Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig’s disease,” is a progressive neurodegenerative disease that attacks nerve cells in the brain and the spinal cord. The disease results in the progressive degeneration of motor neurons, causing the brain to lose control of muscle movement. With all voluntary muscle action affected, patients in the later stages of the disease become totally paralyzed.

Muscle weakness is the most common initial sign of ALS, occurring in approximately 60% of patients. Early symptoms usually include tripping, dropping things, abnormal fatigue of the arms and/or legs, slurred speech, muscle cramps and twitches and/or uncontrollable periods of laughing or crying. The hands and feet may be affected first, causing difficulty in lifting, walking or using the hands for the activities of daily living such as dressing, washing and buttoning clothes.

There is currently no cure for ALS. Treatment focuses on relieving symptoms and maintaining an optimal quality of life. Treatment is based on individual therapy and the continual adaptation of medications. Physical therapy is another important part of treatment and helps to relieve cramping and muscular pain. Other therapies, such as occupational therapy and speech therapy, are also used in treatment.

Power3 Medical Products, Inc. (OTC.BB:PWRM) is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:

Breast Cancer Chemotherapeutic Drug Resistance
Alzheimer’s Disease Leukemia
ALS (Lou Gehrig’s Disease) Gastrointestinal Disease
Parkinson’s Disease Metabolic Syndrome

The NuroPro Blood Test is Power3’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease . Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

The NuroPro Test is currently in the development stages. The company has completed proof-of-concept and clinical validation studies, with results exceeding expectations. Currently, Power3 has commenced a three hundred patient clinical validation study of its NuroPro diagnostic test for Alzheimer’s disease and Parkinson’s disease.

************************************************

Dynamics Research Corp. (Nasdaq:DRCO) announced that it will participate in the following institutional investor events this month: May 24: B. Riley 12th Annual Investor Conference in Santa Monica and May 25: Stephens Spring Investor Conference in New York.

Dynamics Research Corporation provides management consulting, engineering, technical, and information technology (IT) services and solutions to federal and state governments.

************************************************

Autodesk, Inc. (Nasdaq:ADSK) reported financial results for the first quarter of fiscal year 2012. Revenue was $528 million, an increase of 11 percent compared to the first quarter of fiscal 2011. GAAP operating margin was 15 percent, compared to 11 percent in the first quarter of fiscal 2011. Non-GAAP operating margin was 23 percent, compared to 20 percent in the first quarter of fiscal 2011. GAAP diluted earnings per share were $0.29, compared to $0.16 in the first quarter of fiscal 2011. Non-GAAP diluted earnings per share were $0.40, compared to $0.29 in the first quarter of fiscal 2011. Cash flow from operating activities was $128 million, compared to $139 million in the first quarter of fiscal 2011 and $176 million in the fourth quarter of fiscal 2011.

Autodesk, Inc. operates as a design software and service company. The company Platform Solutions and Emerging Business and Other segment provides AutoCAD computer-aided design application for professional design, drafting, detailing, and visualization; and AutoCAD LT software for professional drafting and detailing.

*************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 2,000,000 shares of 144 restricted stocks from the company for 12 months of advertisement services for Cleantech Transit, Inc. (CLNO.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Internet marketing helps you to grow in your business as it brings in qualified leads from potential customers who are looking for products and services of your company. Applying online marketing techniques saves you plenty of time and money. If you hire a Internet marketing company who gives you services of Internet marketing then you are just required to manage just one relationship. The majority of companies that offer Internet marketing and e-marketing services include website design and development, search engine optimization, pay per click and email marketing. This saves you plenty of time that would otherwise get wasted in finding these services.

Crown Equity Holdings Inc. (CRWE.OB), together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

Crown Equity Holdings, Inc. recently announced that it has extended its CRWENEWSWIRE global platform web presence and is now publishing online news and information to the following countries: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Ireland, Italy, Japan, Malaysia, Mexico, New Zealand, Russia, Singapore, South Africa, South Korea, Spain, Taiwan, United Arab Emirates and the United Kingdom, using their specific country code domain and native language.

“In addition to publishing to the mentioned countries, Crown Equity Holdings Inc. has also established online publishing sites for over 660 various cities within those countries,” stated Arnulfo Saucedo-Bardan, Chairman of the Board for Crown Equity Holdings Inc.

For more information, visit http://www.crownequityholdings.com

***************************************************

Altra Holdings, Inc. (Nasdaq:AIMC) announced that President and Chief Executive Officer Carl Christensen, and Vice President and Chief Financial Officer Christian Storch, recently presented at the Bank of America Merrill Lynch Smid Cap Conference in Boston. The presentation was webcast at 4:10 p.m. ET on Tuesday, May 10, 2011 and is available through the Investor Relations section of the company’s website at www.altramotion.com.

Altra Holdings, Inc., together with its subsidiary, Altra Industrial Motion, Inc., designs, produces, and markets a range of mechanical power transmission and motion control products primarily in North America, Europe, and Asia.

***************************************************

The Knot, Inc. (NASDAQ:KNOT) reported financial results for the first quarter ended March 31, 2011. Total revenue for the quarter was $27.5 million, flat compared to the first quarter of 2010. The results were again led by online advertising as national online advertising grew 18% and local online advertising was up 15% compared to the first quarter last year. The increase in both national and local online advertising was boosted by 15% growth in publishing as both national and local print publications saw solid gains in advertising. These gains were mostly offset by the anticipated declines in registry services and merchandise revenue, which were primarily the result of the change in the Macy’s relationship announced last January.

The Knot, Inc. provides multiplatform media services to the wedding, newlywed, and pregnancy markets in the United States.

*************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Capital City Bank Group, Inc. (Nasdaq:CCBG) will address analysts and investors attending the 2011 Gulf South Bank Conference on May 10, 2011.

CCBG is scheduled to present at 8:45 a.m. ET. J. Kimbrough Davis, executive vice president and chief financial officer, and Dale A. Thompson, executive vice president and chief credit officer, will discuss CCBG strategy, recent business developments and market opportunities.

*************************

Power3 Medical Products, Inc. (PWRM.OB)

Power3 Medical Products, Inc., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced PWRM management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

In addition, PWRM is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by PWRM several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for PWRM’s depressed stock price and have distracted the company from its mission, PWRM plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, PWRM will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. PWRM intends to appeal this decision.

“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of PWRM. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. PWRM plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in 2011.

Power3 Medical Products, Inc., a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. The company was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. Power3 Medical Products, Inc . was founded in 1992 and is based in The Woodlands, Texas.

To discover more about PWRM visit: http://www.Power3Medical.com

*************************

HCC Insurance Holdings, Inc. (NYSE:HCC) recently reported that HCC Chief Executive Officer John N. Molbeck, Jr. and President Christopher J.B. Williams will be presenting at the Tenth Annual JMP Securities Research Conference in San Francisco, California on Tuesday, May 10, 2011, beginning at 9:00 a.m. Pacific Daylight Time.

*************************

Orofino Gold Corp. (ORFG.PK)

Orofino Gold Corp. (OTCQB: ORFG) has been working with Colombian utilities supplier Electricaribe to establish power to the villages of the local populations within Orofino’s concessions. Buena Sena was supplied with electricity in July of 2010. And by mid May, Orofino expects to have complete electrical service established at La Azul.

La Azul’s connection is coming from an intermediate station operating at 13,200 cycles/second located in the town of Rio Viejo. Once operational, La Azul’s infrastructure is expected to initially be tied into a 50 kva transformer.

“When the power connection was established in Buena Sena last year, it was a very important date for that community,” explains Orofino President and CEO, Mr. Ary F. Pernett Marquez. “Imagine what it would be like to have publicly supplied electricity for the first time in your life. We’re excited that the residents and miners of La Azul will also be getting the benefits of such a vital piece of infrastructure.”

In addition to providing a critical piece of infrastructure to promote growth of La Azul village, Orofino expects the connection to the region’s power grid to significantly improve production capabilities of mine workers. As current production is being performed with outdated equipment powered only by generators, connecting La Azul to the region’s power grid will enable Orofino to introduce modern mining equipment and technology.

One of the most significant and noteworthy industrial use of gold is in the manufacture of electronics. Solid state electronic devices do not use a great amount of voltage and currents and which can be interrupted due to corrosion or tarnish at the contact points. Gold nonetheless is the very efficient conductor that is able to take the small currents and that will not become corroded. The electronic components that are made with gold are also very dependable. Gold is used in a lot of electronic components such as in connectors, switch and relay contacts, soldered joints, connection strips, connecting wires etc. almost all of the modern electronic devices we have these days have a little amount of gold in them. Some of the devices that one utilizes every day have gold in them such as in the case of cell phones, personal digital assistants, calculators and many other little electronic devices and obviously the bigger electronic appliances also have gold in them such as in the case of televisions etc.

ORFG’s Mission

To become a 100,000 ounce gold producer from first mine and to replicate this on each of the current optioned properties.

The vision of Orofino Gold Corp.:

* To become a good Joint Venture Partner

* To become a premier Mid Tier precious metals mining operation in Colombia

* To fast track first mine to commercial production.

For more information about Orofino Gold Corp., please visit their website: http://www.orofinogold.com

*************************

BPZ Resources, Inc., d/b/a BPZ Energy (NYSE:BPZ), an independent exploration and production company, recently reported that it has scheduled a conference call and webcast to discuss first quarter 2011 results on Tuesday, May 17, 2011, at 10:00 a.m. CDT (11:00 a.m. EDT).

***********************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has previously received 500,000 shares of (144) restricted common stock and 500,000 shares of free trading shares from a third party (QU CUI You) for six months of advertisement services (which has expired) for Orofino Gold Corp. (PINK SHEETS:ORFG).